Table of Content

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.2.1 MARKETS COVERED 14
1.2.2 YEARS CONSIDERED FOR THE STUDY 14
1.3 CURRENCY 15
1.4 LIMITATIONS 15
1.5 STAKEHOLDERS 15

2 RESEARCH METHODOLOGY 16
2.1 SECONDARY DATA 17
2.1.1 KEY DATA FROM SECONDARY SOURCES 17
2.2 PRIMARY DATA 18
2.2.1 KEY DATA FROM PRIMARY SOURCES 18
2.3 MARKET SIZE ESTIMATION 19
2.3.1 BOTTOM-UP APPROACH 19
2.3.2 TOP-DOWN APPROACH 20
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.5 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23

4 PREMIUM INSIGHTS 27
4.1 VITAMIN D: MARKET OVERVIEW 27
4.2 NORTH AMERICA: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2019) 28
4.3 GEOGRAPHICAL SNAPSHOT OF THE VITAMIN D THERAPY MARKET 29

5 MARKET OVERVIEW 30
5.1 INTRODUCTION 30
5.2 MARKET DYNAMICS 30
5.2.1 DRIVERS 31
5.2.1.1 Growing awareness about vitamin d deficiency among consumers 31
5.2.1.2 Presence of a large target patient population 31
5.2.2 MARKET OPPORTUNITIES 32
5.2.2.1 Growth opportunities in countries with a high prevalence of undernutrition 32
5.2.3 MARKET CHALLENGES 32
5.2.3.1 Fortified foods 32

6 ROLE OF VITAMIN D IN DISEASE PROGRESSION 33
6.1 ROLE OF VITAMIN D IN THE PREVENTION AND TREATMENT OF CANCER 33
6.2 ROLE OF VITAMIN D IN THE PREVENTION AND TREATMENT OF DIABETES 33
6.3 ROLE OF VITAMIN D IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES 34

7 VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 35
7.1 INTRODUCTION 36
7.2 ORAL ROUTE OF ADMINISTRATION 36
7.2.1 ORAL ROUTE OF ADMINISTRATION LIKELY TO DOMINATE THE VITAMIN D THERAPY MARKET DUE TO HIGH PATIENT COMPLIANCE 36
7.3 PARENTERAL ROUTE OF ADMINISTRATION 37
7.3.1 USE OF PARENTERALS IS MOSTLY RESERVED FOR HYPOVITAMINOSIS D 37

8 VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 39
8.1 INTRODUCTION 40
8.2 PRESCRIPTION DRUGS 40
8.2.1 GROWING HYPOVITAMINOSIS D PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET 40
8.3 OVER-THE-COUNTER DRUGS 41
8.3.1 EASE OF PURCHASE LEADS TO PEOPLE OPTING FOR OTC 41

9 VITAMIN D THERAPY MARKET, BY APPLICATION 42
9.1 INTRODUCTION 43
9.2 OSTEOPOROSIS 43
9.2.1 FRACTURES AND BROKEN BONES LEADING TO RISE IN VITAMIN D THERAPY MARKET 43
9.3 RICKETS 44
9.3.1 UPDATED GUIDELINES ON DAILY DIETARY INTAKE OF VITAMIN D LIKELY TO LOWER INCIDENCE OF RICKETS 44
9.4 MUSCLE WEAKNESS 45
9.4.1 EVIDENCE INDICATES IMPACT OF VITAMIN D ON ATHLETE AND INJURY PROFILES 45
9.5 AUTOIMMUNE DISORDERS 46
9.5.1 RESEARCH IS REQUIRED TO UNDERSTAND THE ROLE OF VITAMIN D IN AUTOIMMUNE DISORDERS 46
9.6 SKIN DISEASES 47
9.6.1 IMMUNOMODULATORY ACTIVITY OF VITAMIN D LIKELY TO INCREASE THE MARKET FOR PSORIASIS 47
9.7 OTHER APPLICATIONS 48
?

10 VITAMIN D THERAPY MARKET, BY AGE GROUP 49
10.1 INTRODUCTION 50
10.2 SENIOR ADULTS 50
10.2.1 INCREASING INCIDENCE OF OSTEOPOROSIS AMONG SENIOR ADULTS HAS DRIVEN DEMAND FOR VITAMIN D 50
10.3 ADULTS 51
10.3.1 SEDENTARY LIFESTYLES ARE LEADING TO HYPOVITAMINOSIS D AMONG ADULTS 51
10.4 CHILDREN 52
10.4.1 HIGH PREVALENCE OF RICKETS AMONG CHILDREN IS DRIVING MARKET GROWTH 52

11 VITAMIN D THERAPY MARKET, BY REGION 53
11.1 INTRODUCTION 54
11.2 NORTH AMERICA 54
11.2.1 US 58
11.2.1.1 US to dominate the North American vitamin D therapy market 58
11.2.2 CANADA 60
11.2.2.1 Limited endogenous synthesis and limited dietary sources are the major factors responsible for vitamin D deficiency in the Canadian population 60
11.3 EUROPE 62
11.3.1 UK 64
11.3.1.1 Vitamin D deficiency is prevalent among all age groups in the UK 64
11.3.2 GERMANY 66
11.3.2.1 High prevalence of osteoporosis is expected to be the key factor driving market growth in Germany 66
11.3.3 FRANCE 68
11.3.3.1 Vitamin D levels are declining in France 68
11.3.4 REST OF EUROPE 70
11.4 ASIA PACIFIC 72
11.4.1 CHINA 75
11.4.1.1 Heavy air pollution and sedentary lifestyles are driving market growth in China 75
11.4.2 JAPAN 77
11.4.2.1 Increasing incidence of vitamin D deficiency in Japan to drive market growth 77
11.4.3 INDIA 79
11.4.3.1 A large part of India’s population is vitamin D-deficient 79
11.4.4 REST OF ASIA PACIFIC 81
11.5 REST OF THE WORLD 83
?

12 COMPETITIVE LANDSCAPE 85
12.1 OVERVIEW 85
12.2 MARKET RANKING ANALYSIS, 2018 85
12.3 KEY STRATEGIES 86
12.3.1 ACQUISITIONS AND COLLABORATIONS, 2015–2018 86
12.4 COMPETITIVE LEADERSHIP MAPPING (2018) 86
12.4.1 VISIONARY LEADERS 87
12.4.2 INNOVATORS 87
12.4.3 DYNAMIC DIFFERENTIATORS 87
12.4.4 EMERGING COMPANIES 87

13 COMPANY PROFILES 89
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 NOVARTIS AG 89
13.2 PFIZER INC 91
13.3 GLAXOSMITHKLINE PLC 93
13.4 MERCK & CO., INC. 95
13.5 ABBOTT 97
13.6 SANOFI 99
13.7 TORRENT PHARMACEUTICALS LTD. 100
13.8 SUN PHARMACEUTICAL INDUSTRIES LTD. 102
13.9 ALKEM LABORATORIES LTD. 103
13.10 CADILA HEALTHCARE LTD. 104

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14 APPENDIX 106
14.1 INSIGHTS OF INDUSTRY EXPERTS 106
14.2 DISCUSSION GUIDE 107
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 109
14.4 AVAILABLE CUSTOMIZATIONS 111
14.5 RELATED REPORTS 111
14.6 AUTHOR DETAILS 112



List of Figures



FIGURE 1 RESEARCH DESIGN 16
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 18
FIGURE 3 VITAMIN D THERAPY MARKET: BOTTOM-UP APPROACH 19
FIGURE 4 VITAMIN D THERAPY MARKET: TOP-DOWN APPROACH 20
FIGURE 5 DATA TRIANGULATION METHODOLOGY 21
FIGURE 6 VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2019 VS. 2024 (USD MILLION) 23
FIGURE 7 VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2019 VS. 2024 (USD MILLION) 24
FIGURE 8 VITAMIN D THERAPY MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION) 24
FIGURE 9 VITAMIN D THERAPY MARKET, BY AGE GROUP, 2019 VS. 2024 (USD MILLION) 25
FIGURE 10 VITAMIN D THERAPY MARKET, BY REGION, 2019 VS. 2024 (USD MILLION) 25
FIGURE 11 GROWING AWARENESS ABOUT VITAMIN D DEFICIENCY AND LARGE PATIENT POPULATION TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 27
FIGURE 12 ORAL ROUTE OF ADMINISTRATION TO DOMINATE THE NORTH AMERICAN VITAMIN D THERAPY MARKET IN 2019 28
FIGURE 13 ASIAN COUNTRIES TO REGISTER HIGH GROWTH RATES DURING THE FORECAST PERIOD 29
FIGURE 14 VITAMIN D THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 30
FIGURE 15 NORTH AMERICA: VITAMIN D THERAPY MARKET SNAPSHOT 55
FIGURE 16 ASIA PACIFIC: VITAMIN D THERAPY MARKET SNAPSHOT 72
FIGURE 17 KEY DEVELOPMENTS IN THE VITAMIN D THERAPY MARKET FROM 2015 TO 2018 85
FIGURE 18 VITAMIN D THERAPY MARKET RANKING, BY KEY PLAYER, 2018 85
FIGURE 19 MNM DIVE-VENDOR COMPARISON MATRIX: VITAMIN D THERAPY MARKET 88
FIGURE 20 NOVARTIS AG: COMPANY SNAPSHOT (2018) 89
FIGURE 21 PFIZER INC.: COMPANY SNAPSHOT (2018) 91
FIGURE 22 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2018) 93
FIGURE 23 MERCK & CO., INC.: COMPANY SNAPSHOT (2018) 95
FIGURE 24 ABBOTT: COMPANY SNAPSHOT (2018) 97
FIGURE 25 SANOFI: COMPANY SNAPSHOT 99
FIGURE 26 TORRENT: COMPANY SNAPSHOT (2018) 100
FIGURE 27 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2018) 102
FIGURE 28 ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT (2018) 103
FIGURE 29 CADILA HEALTHCARE LTD.: COMPANY SNAPSHOT (2018) 104

 

List of Tables



TABLE 1 VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 36
TABLE 2 VITAMIN D THERAPY MARKET FOR ORAL ROUTE OF ADMINISTRATION BY REGION, 2017–2024 (USD MILLION) 37
TABLE 3 VITAMIN D THERAPY MARKET FOR PARENTERAL ROUTE OF ADMINISTRATION BY REGION, 2017–2024 (USD MILLION) 38
TABLE 4 VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 40
TABLE 5 VITAMIN D THERAPY MARKET FOR PRESCRIPTION DRUGS BY REGION, 2017–2024 (USD MILLION) 40
TABLE 6 VITAMIN D THERAPY MARKET FOR OTC DRUGS, BY REGION 2017–2024 (USD MILLION) 41
TABLE 7 VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 43
TABLE 8 VITAMIN D THERAPY MARKET FOR OSTEOPOROSIS, BY REGION 2017–2024 (USD MILLION) 44
TABLE 9 VITAMIN D THERAPY MARKET FOR RICKETS, BY REGION 2017–2024 (USD MILLION) 45
TABLE 10 VITAMIN D THERAPY MARKET FOR MUSCLE WEAKNESS BY REGION, 2017–2024 (USD MILLION) 46
TABLE 11 VITAMIN D THERAPY MARKET FOR AUTOIMMUNE DISORDERS BY REGION, 2017–2024 (USD MILLION) 47
TABLE 12 VITAMIN D THERAPY MARKET FOR SKIN DISEASES, BY REGION 2017–2024 (USD MILLION) 47
TABLE 13 VITAMIN D THERAPY MARKET FOR OTHER APPLICATIONS, BY REGION 2017–2024 (USD MILLION) 48
TABLE 14 VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 50
TABLE 15 VITAMIN D THERAPY MARKET FOR SENIOR ADULTS, BY REGION 2017–2024 (USD MILLION) 51
TABLE 16 VITAMIN D THERAPY MARKET FOR ADULTS, BY REGION 2017–2024 (USD MILLION) 51
TABLE 17 VITAMIN D THERAPY MARKET FOR CHILDREN, BY REGION 2017–2024 (USD MILLION) 52
TABLE 18 VITAMIN D THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION) 54
TABLE 19 NORTH AMERICA: VITAMIN D THERAPY MARKET, BY COUNTRY 2017–2024 (USD MILLION) 56
TABLE 20 NORTH AMERICA: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION) 56
TABLE 21 NORTH AMERICA: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION) 56
TABLE 22 NORTH AMERICA: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 57
TABLE 23 NORTH AMERICA: VITAMIN D THERAPY MARKET, BY AGE GROUP 2017–2024 (USD MILLION) 57
TABLE 24 US: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 58
TABLE 25 US: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 58
TABLE 26 US: VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 59
TABLE 27 US: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 59
TABLE 28 CANADA: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 60
TABLE 29 CANADA: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 60
TABLE 30 CANADA: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 61
TABLE 31 CANADA: VITAMIN D THERAPY MARKET, BY AGE GROUP 2017–2024 (USD MILLION) 61
TABLE 32 EUROPE: VITAMIN D THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 62
TABLE 33 EUROPE: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 62
TABLE 34 EUROPE: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 63
TABLE 35 EUROPE: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 63
TABLE 36 EUROPE: VITAMIN D THERAPY MARKET, BY AGE GROUP 2017–2024 (USD MILLION) 63
TABLE 37 UK: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 64
TABLE 38 UK: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 65
TABLE 39 UK: VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 65
TABLE 40 UK: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 65
TABLE 41 GERMANY: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 66
TABLE 42 GERMANY: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 66
TABLE 43 GERMANY: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 67
TABLE 44 GERMANY: VITAMIN D THERAPY MARKET, BY AGE GROUP 2017–2024 (USD MILLION) 67
TABLE 45 FRANCE: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 68
TABLE 46 FRANCE: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 68
TABLE 47 FRANCE: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 69
TABLE 48 FRANCE: VITAMIN D THERAPY MARKET, BY AGE GROUP 2017–2024 (USD MILLION) 69
TABLE 49 ROE: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 70
TABLE 50 ROE: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 70
TABLE 51 ROE: VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 71
TABLE 52 ROE: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 71
TABLE 53 APAC: VITAMIN D THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 54 APAC: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 73
TABLE 55 APAC: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 73
TABLE 56 APAC: VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 74
TABLE 57 APAC: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 74
TABLE 58 CHINA: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 75
TABLE 59 CHINA: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 75
TABLE 60 CHINA: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 76
TABLE 61 CHINA: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 76
TABLE 62 JAPAN: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 77
TABLE 63 JAPAN: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 77
TABLE 64 JAPAN: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 78
TABLE 65 JAPAN: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 78
TABLE 66 INDIA: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 79
TABLE 67 INDIA: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 79
TABLE 68 INDIA: VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 80
TABLE 69 INDIA: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 80
TABLE 70 ROAPAC: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 81
TABLE 71 ROAPAC: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 81
TABLE 72 ROAPAC: VITAMIN D THERAPY MARKET, BY APPLICATION 2017–2024 (USD MILLION) 82
TABLE 73 ROAPAC: VITAMIN D THERAPY MARKET, BY AGE GROUP 2017–2024 (USD MILLION) 82
TABLE 74 ROW: VITAMIN D THERAPY MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 83
TABLE 75 ROW: VITAMIN D THERAPY MARKET, BY PURCHASING PATTERN 2017–2024 (USD MILLION) 83
TABLE 76 ROW: VITAMIN D THERAPY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 84
TABLE 77 ROW: VITAMIN D THERAPY MARKET, BY AGE GROUP, 2017–2024 (USD MILLION) 84